| abstract |
The present invention relates to compounds of the formula I and to pharmaceutical compositions containing them. The compounds of general formula (I) are useful in the treatment of a variety of disorders such as TNF-a, IL-1b, IL-6 and / or IL-8 mediated diseases or other disorders such as pain and diabetes. More particularly, the compounds of the present invention are useful in the prophylaxis and treatment of inflammatory diseases and conditions. The present invention relates to intermediates and processes for the preparation of compounds. In the formula (I), the substituents are as defined herein, for example, X is oxygen, sulfur or -NR5, wherein (y) -VC (R) W- is (a), (b), ( c), (d), (e), (f) or (g) provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclic groups in the group -VC (R) W- An integer from 0 to 3; U is -NR21 or -CHR21; and n is an integer from 1 to 3; R3 and R4 are independently -ZY, with the proviso that R4 is other than hydrogen, substituted aryl, (substituted aryl) methyl or (substituted aryl) ethyl, and aryl, heteroaryl, cycloalkyl, and the total number of heterocyclic groups in each -Y and -ZY group is an integer from 0 to 3; wherein each Z is independently (1) alkyl, alkenyl or alkynyl, which may be optionally substituted with different groups; (2) a heterocyclic group optionally substituted with various groups; or (3) aryl or heteroaryl, which may be substituted with particular moieties; each Y is independently (1) hydrogen; (2) halogen, cyano or nitro; (3) -C (O) -R 20, -C (O) -OR 21, -C (O) -NR 5 R 21 or -C (NR 5) -NR 5 R 21, (4) -OR 21, -OC (O) -R 21 , -OC (O) -NR 5 R 21 or -OC (O) -NR 22 -S (O) 2 -R 20; (5) -SR21, -S (O) -R20, -S (O) 2 -R20, -S (O) 2 -NR5R21, -S (O) 2 -NR22-C (O) -R21, -S (O) 2-NR22-C (O) -OR20 or -S (O) 2-NR22-C (O) -NR5R21; R11 and R12 are optionally substituted aryl or heteroaryl. SHE |